On December 30, Poly Pharmaceutical (300630) announced the progress of the investigation it is under and issued a warning regarding the risks associated with its convertible bond trading. According to the notice from the China Securities Regulatory Commission (CSRC), the company is being investigated due to suspected violations of information disclosure laws and regulations. The company stated in the announcement that if the facts confirmed by the CSRC indicate severe legal violations that warrant forced delisting, the company's stocks may face the risk of being subjected to significant legal violations resulting in compulsory delisting.

Additionally, starting from February 9, 2025, the company's convertible bonds will enter the repurchase period. During this period, if the company's stock closes below 70% of the current conversion price for any consecutive thirty trading days, the company may face risks associated with early redemption requests for the principal and interest of the repurchased convertible bonds, which may result in an inability to fulfill full payment. The company is actively cooperating with the CSRC's investigation and will fulfill its duty of information disclosure in a timely manner based on the progress of related matters.

https://finance.eastmoney.com/a/202412303282894587.html